MedTrace Logo

ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa

NCT06200558 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 534

Last updated 2025-11-26

No results posted yet for this study

Summary

Study wants to explore real-world data in three distinct settings

* Patients with metachronous or de novo mCSPC treated with ADT+ARSI or ADT+ARSI+docetaxel \_ARON-3S
* Patients receiving Lutetium-177 PSMA for mCRPC \_ ARON-3Lu
* Patients treated with PARP inhibitors (alone or combined with ARSI) for CRPC \_ ARON-3GEN

Conditions

Sponsors & Collaborators

  • Hospital of Macerata

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-31
Primary Completion
2024-05-31
Completion
2028-02-01

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06200558 on ClinicalTrials.gov